← Back to Clinical Trials
Recruiting NCT06796894

NCT06796894 Symptoms, Respiratory Dysfunction and Frailty Level in Allergic and Eosonophilic Asthmatics

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06796894
Status Recruiting
Phase
Sponsor Hacettepe University
Condition Asthma
Study Type OBSERVATIONAL
Enrollment 60 participants
Start Date 2024-08-01
Primary Completion 2026-10-30

Eligibility & Interventions

Sex All sexes
Min Age 35 Years
Max Age 75 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 60 participants in total. It began in 2024-08-01 with a primary completion date of 2026-10-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of this study is to determine the level of respiratory dysfunction, symptoms and frailty in patients with asthma according to different endophenotypes (allergic and eosonophilic asthma). In the light of the data obtained, it is thought that rehabilitation approaches that can be determined according to different endophenotypes in line with the evaluated parameters will guide health professionals working in this field. Hypotheses H0: There is no difference between allergic and eosonophilic asthmatics in terms of pulmonary function, respiratory dysfunction, symptoms, dyspnoea, fatigue, rhinitis, perception of breathlessness in activities of daily living, asthma control, level of frailty or quality of life. H1: There is a difference between individuals with allergic and eosonophilic asthma in terms of pulmonary function, respiratory dysfunction, symptoms, dyspnoea, fatigue, rhinitis, perception of breathlessness in activities of daily living, asthma control, level of frailty or quality of life.

Eligibility Criteria

Inclusion Criteria: * Age between 35-75 years, * Diagnosed with allergic or eosonophilic asthma according to the Global Strategy for the Prevention and Treatment of Asthma (GINA). Exclusion Criteria: * Known cognitive impairment, * Having had an acute asthma attack in the last 6 weeks, * Having changed medication in the last 4 weeks.

Contact & Investigator

Central Contact

Ebru Calik Kutukcu, PhD

✉ ebru.calik@hacettepe.edu.tr

📞 3123051576

Principal Investigator

Ebru Calik Kutukcu

PRINCIPAL INVESTIGATOR

Hacettepe University

Frequently Asked Questions

Who can join the NCT06796894 clinical trial?

This trial is open to participants of all sexes, aged 35 Years or older, up to 75 Years, studying Asthma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06796894 currently recruiting?

Yes, NCT06796894 is actively recruiting participants. Contact the research team at ebru.calik@hacettepe.edu.tr for enrollment information.

Where is the NCT06796894 trial being conducted?

This trial is being conducted at Ankara, Turkey (Türkiye).

Who is sponsoring the NCT06796894 clinical trial?

NCT06796894 is sponsored by Hacettepe University. The principal investigator is Ebru Calik Kutukcu at Hacettepe University. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology